miR-17-92 and miR-192 inhibited the progression of cancers via suppressing tumour angiogenesis through targeting multiple tumour angiogenesis-inducing genes, TGFBR2 (transforming growth factor, beta receptor 2), HIF1α and VEGFA in vivo and in vitro [110,111]. This evidence concerns the gene HIF1A and cancer.